Efficacy of favipiravir (T‐705) in nonhuman primates infected with Ebola virus or Marburg virus

@article{Bixler2017EfficacyOF,
  title={Efficacy of favipiravir (T‐705) in nonhuman primates infected with Ebola virus or Marburg virus},
  author={Sandra L Bixler and Thomas M. Bocan and Jay Wells and Kelly S Wetzel and Sean A. van Tongeren and Lian Cheng Dong and Nicole L. Garza and Ginger C. Donnelly and Lisa H. Cazares and Jonathan E. Nuss and Veronica Soloveva and Keith A. Koistinen and Lisa Welch and Carol Epstein and Li-Fang Liang and Dennis H. Giesing and Robert P. Lenk and Sina Bavari and Travis Warren},
  journal={Antiviral Research},
  year={2017},
  volume={151},
  pages={97–104}
}
ABSTRACT Favipiravir is a broad‐spectrum antiviral agent that has demonstrated efficacy against Ebola virus (EBOV) in rodents. However, there are no published reports of favipiravir efficacy for filovirus infection of nonhuman primates (NHPs). Here we evaluated the pharmacokinetic profile of favipiravir in NHPs, as well as in vivo efficacy against two filoviruses, EBOV and Marburg virus (MARV). While no survival benefit was observed in two studies employing once‐ or twice‐daily oral dosing of… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Screening and Identification of Marburg Virus Entry Inhibitors Using Approved Drugs

Li Zhang, Shan Lei, +6 authors Youchun Wang
  • Virologica Sinica
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 22 REFERENCES

Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014.

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2016
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL